| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 01/02/2002 | CN1329019A A novel polypeptide-NAD-dependent 2-hydroxy acid hydrogenase family protein 11 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329017A A novel polypeptide-myelin PO protein 9 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329016A A novel polypeptide-RCC1 protein 9.79 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329015A A novel polypeptide-slicing factor Prp4 protein 19.58 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329014A A novel polypeptide-activating GTP enzyme pratein negative regulatory factor 9.68 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329013A A novel polypeptide-human nucleotide excision repair protein 13.31 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1329010A A novel polypeptide-histidyl-tRNA synthetase analogous protein 10.45 and polynucleotide for coding this polypeptide |
| 01/02/2002 | CN1328875A Method for preparing 3,4-dichlorophenylnitrile by using ammonia oxidation process and its special-purpose catalyst |
| 01/01/2002 | US6335433 nrdD |
| 01/01/2002 | US6335428 Monoclonal antibodies; for use as drug screening tool |
| 01/01/2002 | US6335424 ribG |
| 01/01/2002 | US6335199 Gene therapy |
| 01/01/2002 | US6335193 Isolated colonocytes |
| 01/01/2002 | US6335181 Generating polypeptide; for use in the diagnosis, prevention and treatment of bacterial infection |
| 01/01/2002 | US6335180 Nucleic acid sequences encoding capsaicin receptor and uses thereof |
| 01/01/2002 | US6335175 Anti-human pre-B cell receptor antibody |
| 01/01/2002 | US6335174 Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific CD4, CD8 cytotoxic and suppressor T cells and interleukin-10 |
| 01/01/2002 | US6335163 Aggolomeration of receptor proteins; for use in diagnosis, treatment, and prevention of tumors, parasitic, bacterial and viral infections; for use in gene therapy |
| 01/01/2002 | US6335160 Methods and compositions for polypeptide engineering |
| 01/01/2002 | US6335159 Retinoic acid receptor ε(rarε) |
| 01/01/2002 | US6335158 Immunologically active peptide of given amino acid sequence which binds antibodies against retroviruses of the hiv type; diagnostic kits |
| 01/01/2002 | US6335020 Allergenic peptides from ragweed pollen |
| 01/01/2002 | US6335019 Methods for treating sensitivity to protein allergen using peptides which include a T cell epitope recognized by a T cell receptor specific for the protein allergen |
| 01/01/2002 | US6335017 Compositions and methods for treating viral infections |
| 01/01/2002 | US6335014 Medicament for suppressing cancer metastasis |
| 01/01/2002 | CA1341331C Viral vector and recombinant dna coding for one or more structural protein (ha, f and/or np) of a morbillivirus, infected cell culture, resulting proteins, vaccine and antibodies |
| 12/29/2001 | CA2351904A1 Target |
| 12/27/2001 | WO2001098539A2 Gene markers for lung cancer |
| 12/27/2001 | WO2001098534A2 Matrix screening method |
| 12/27/2001 | WO2001098523A2 Detection method of genetic recombinant food and detection kit of that |
| 12/27/2001 | WO2001098499A1 Antigenic polypeptides |
| 12/27/2001 | WO2001098497A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | WO2001098493A1 Insulin-like growth factor-binding protein |
| 12/27/2001 | WO2001098491A2 Osteolevin gene polymorphisms |
| 12/27/2001 | WO2001098490A1 A g-protein coupled receptor |
| 12/27/2001 | WO2001098489A1 Nucleotide and amino acid sequences of a cellular inhibitor of the dna replication in the epstein-barr herpes virus |
| 12/27/2001 | WO2001098486A1 Mutation associated with epilepsy |
| 12/27/2001 | WO2001098471A2 Human phosphodiesterases |
| 12/27/2001 | WO2001098470A2 Recombinant proteolytic tryptases, active site mutants thereof, and methods of making same |
| 12/27/2001 | WO2001098468A2 Proteases |
| 12/27/2001 | WO2001098361A2 Agonist anti-trk-c monoclonal antibodies |
| 12/27/2001 | WO2001098360A2 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | WO2001098359A2 Cyr61 as a target for treatment and diagnosis of breast cancer |
| 12/27/2001 | WO2001098358A2 Compositions for identification and isolation of stem cells |
| 12/27/2001 | WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | WO2001098354A2 Human receptors |
| 12/27/2001 | WO2001098353A2 Secreted proteins |
| 12/27/2001 | WO2001098350A2 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | WO2001098344A2 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | WO2001098339A2 Compositions and methods for the therapy and diagnosis of breast cancer |
| 12/27/2001 | WO2001098332A2 Secreted redox proteins |
| 12/27/2001 | WO2001098324A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 12/27/2001 | WO2001098323A2 G-protein coupled receptors |
| 12/27/2001 | WO2001097846A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/27/2001 | WO2001097844A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| 12/27/2001 | WO2001097843A2 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | WO2001097842A1 Curing method for pathologic syndrome and a medicinal preparation |
| 12/27/2001 | WO2001097840A1 Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
| 12/27/2001 | WO2001097608A2 Cyk-4 polypeptides, dna molecules encoding them and their use in screening methods |
| 12/27/2001 | WO2001075087A8 Subtilisin variants |
| 12/27/2001 | WO2001055310A3 Nucleic acids, proteins, and antibodies |
| 12/27/2001 | WO2001049711A3 Nucleic acids encoding (poly)peptides having chips activity |
| 12/27/2001 | WO2001046256A3 Vesicle trafficking proteins |
| 12/27/2001 | WO2001044438A3 Serological diagnostic method with rickettsia pulicis bacterium |
| 12/27/2001 | WO2001038490A3 ISOLATION OF FIVE NOVEL GENES CODING FOR NEW Fc RECEPTORS-TYPE MELANOMA INVOLVED IN THE PATHOGENESIS OF LYMPHOMA/MELANOMA |
| 12/27/2001 | WO2001031019A3 Neisserial antigenic peptides |
| 12/27/2001 | WO2001000799A8 Novel protein and dna thereof |
| 12/27/2001 | US20010056076 Treatment of acute lung injury and fibrosis with antagonists of alphavbeta6 |
| 12/27/2001 | US20010056066 Increasing systemic exposure of a therapeutic protein through two administrations, the second higher dosage than the first; binding the immune cell antigen with saturating amount of monoclonal antibody for example; autoimmune diseases |
| 12/27/2001 | US20010055758 Reagents and methods useful for detecting diseases of the prostate |
| 12/27/2001 | US20010055755 Dendritic marker-expressing macrophage cultures and methods for reactivating latent HCMV |
| 12/27/2001 | US20010055751 PSCA: Prostate stem cell antigen and uses thereof |
| 12/27/2001 | US20010055594 Inhibiting Tumor Necrosis Factor (TNF)-alpha for treating nerve disorders by administering a TNF-alpha inhibitor selected from specified monoclonal antibodies; herniated discs, pain, nucleus pulposus-induced nerve injury, sciatica |
| 12/27/2001 | US20010055593 CD86 (B7) proteins; downmodulating an immune response comprising contacting immune cells with an antibody that binds to at least one B& molecule and a Rapamycin compound; treating autoimmune diseases such as Lupus erythematosis |
| 12/27/2001 | US20010055581 Admixture of a colloidal metal and a biologically-active factor; colloidal metal reduces or eliminated toxicity so the factor can have therapeutic effect; vaccines, treating cancer |
| 12/27/2001 | CA2805216A1 Antigenic polypeptides from staphylococcus |
| 12/27/2001 | CA2414228A1 Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof |
| 12/27/2001 | CA2414015A1 Human receptors |
| 12/27/2001 | CA2414010A1 Secreted redox proteins |
| 12/27/2001 | CA2413986A1 Gp354 nucleic acids and polypeptides |
| 12/27/2001 | CA2413870A1 Recombinant proteolytic tryptases, active site mutants thereof, and methods of making same |
| 12/27/2001 | CA2413866A1 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | CA2413454A1 A g-protein coupled receptor |
| 12/27/2001 | CA2413358A1 Curing method for pathologic syndrome and a medicinal preparation |
| 12/27/2001 | CA2413324A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| 12/27/2001 | CA2412901A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| 12/27/2001 | CA2412484A1 G-protein coupled receptors |
| 12/27/2001 | CA2412215A1 Angiogenesis-modulating compositions and uses |
| 12/27/2001 | CA2412110A1 Osteolevin gene polymorphisms |
| 12/27/2001 | CA2411971A1 Proteases |
| 12/27/2001 | CA2411945A1 Chimeric human papillomavirus (hpv) l1 molecules and uses therefor |
| 12/27/2001 | CA2411756A1 Mutation associated with epilepsy |
| 12/27/2001 | CA2410864A1 Compositions comprising net-4 modulations and their use for treating neoplastic disease |
| 12/27/2001 | CA2410857A1 Matrix screening method |
| 12/27/2001 | CA2410371A1 Methods for enhancing antibody-induced cell lysis and treating cancer |
| 12/27/2001 | CA2410224A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 12/27/2001 | CA2409781A1 Phosphodiesterases |
| 12/27/2001 | CA2409778A1 Secreted proteins |
| 12/26/2001 | CN1328605A Methods for making recombinant cells |
| 12/26/2001 | CN1328571A Human monoclonal antibodies to CTLA-4 |